US stock · Healthcare sector · Biotechnology
Company Logo

BioMarin Pharmaceutical Inc.

BMRNNASDAQ

80.97

USD
+2.11
(+2.68%)
Market Closed
376.60P/E
33Forward P/E
14.53P/E to S&P500
14.992BMarket CAP
- -Div Yield
Upcoming Earnings
26 Jul-1 Aug
Shares Short
5/13/22
12.16M
Short % of Float
6.60%
Short % of Shares Outs.
6.57%
% Held by Insiders
0.54%
% Held by Institutions
98.37%
Beta
0.41
PEG Ratio
1.33
52w. high/low
94.20/71.59
Avg. Daily Volume
1.19M
Return %
Stock
S&P 500
1 year
4.28
(3.64)
3 years
(6.91)
43.84
5 years
(8.15)
68.07
Scale: |
High
Low
37.17
15.53
41.00
13.27
21.23
9.93
28.35
17.70
35.56
23.09
52.96
31.91
80.67
49.71
96.36
55.04
151.75
88.51
105.61
62.12
100.51
80.10
106.74
75.81
100.13
62.88
131.95
68.25
92.20
71.60
94.20
72.00
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.00
1.27
3.00
3.24
3.65
3.94
4.16
3.98
5.13
5.56
6.73
7.53
8.42
9.52
10.29
10.21
10.25
Earnings per share
(0.34)
(0.16)
0.31
(0.00)
2.00
(0.48)
(0.95)
(1.28)
(0.92)
(1.07)
(3.80)
(0.67)
(0.44)
(0.13)
4.75
(0.35)
0.21
FCF per share
(0.88)
(0.59)
(0.66)
(0.02)
(0.30)
(1.21)
(0.22)
(0.91)
(1.31)
(2.81)
(2.27)
(1.19)
(0.70)
(0.64)
(0.29)
1.02
0.13
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.29
0.23
0.57
0.90
0.48
1.38
0.37
0.47
0.81
1.42
0.89
1.14
0.82
0.91
0.76
0.66
0.66
Book Value per sh.
1.39
1.96
2.80
3.21
6.96
6.89
8.45
9.73
10.44
15.00
16.67
16.10
16.76
17.44
22.71
23.62
23.42
Comm.Shares outs.
85
96
99
100
103
112
120
138
146
160
166
174
177
179
181
181
183
Avg. annual P/E ratio
(42.3)
(127.4)
95.2
(3,182.8)
11.1
(59.4)
(40.9)
(49.5)
(77.5)
(107.8)
(22.8)
(133.3)
(210.7)
(619.9)
19.2
(228.1)
376.6
P/E to S&P500
(2.3)
(7.3)
4.4
(44.9)
0.5
(3.6)
(2.8)
(2.9)
(4.3)
(5.4)
(1.0)
(5.7)
(8.4)
(25.6)
0.5
(7.6)
14.5
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
84
122
296
325
376
441
501
548
751
890
1,117
1,314
1,491
1,704
1,860
1,846
1,880
Operating margin
(29.3)%
(47.1)%
13.4%
5.1%
0.1%
(7.7)%
(22.0)%
(28.4)%
(12.4)%
(12.4)%
(71.9)%
(1.1)%
(8.3)%
(5.9)%
(2.0)%
(4.5)%
0.3%
Depreciation (m)
12
1
18
21
28
36
45
47
57
47
97
88
96
105
105
108
107
Net profit (m)
(29)
(16)
31
(0)
206
(54)
(114)
(176)
(134)
(172)
(630)
(117)
(77)
(24)
859
(64)
39
Income tax rate
- -
(4.8)%
7.8%
186.2%
1,057.7%
(23.4)%
3.3%
0.1%
(7.3)%
(11.0)%
24.2%
(226.2)%
45.9%
74.8%
2,129.9%
15.0%
13.1%
Net profit margin
(33.9)%
(13.0)%
10.4%
(0.2)%
54.7%
(12.2)%
(22.8)%
(32.2)%
(17.8)%
(19.3)%
(56.4)%
(8.9)%
(5.2)%
(1.4)%
46.2%
(3.5)%
1.0%
Working capital (m)
288
583
608
390
420
376
573
954
1,190
644
982
1,391
1,533
1,010
1,850
1,735
1,904
Long-term debt (m)
224
497
497
497
378
348
325
656
658
662
661
814
830
486
1,075
1,079
1,080
Equity (m)
118
188
277
322
717
773
1,016
1,341
1,528
2,401
2,766
2,809
2,968
3,122
4,106
4,271
4,391
ROIC
- -
(2.1)%
5.9%
(1.5)%
9.1%
(3.6)%
(7.5)%
(8.0)%
(4.4)%
(4.0)%
(16.8)%
0.3%
(1.4)%
(0.5)%
4.9%
(0.9)%
0.8%
Return on capital
(2.5)%
(1.8)%
5.5%
1.6%
(0.9)%
(2.7)%
(6.9)%
(7.4)%
(3.7)%
(3.2)%
(19.8)%
0.1%
(2.3)%
(1.6)%
(0.2)%
(1.0)%
0.8%
Return on equity
(24.2)%
(8.4)%
11.1%
(0.2)%
28.7%
(7.0)%
(11.3)%
(13.2)%
(8.8)%
(7.2)%
(22.8)%
(4.2)%
(2.6)%
(0.8)%
20.9%
(1.5)%
0.9%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(95.9)%
- -
- -
Capital Structure
29 Apr · 2022 | Q1
All numbers in millions
Total liabilities
$ 1,671
Total assets
$ 6,063
Long-term debt
$ 1,080
Cash and equiv.
$ 605
Goodwill
$ 196
Retained earnings
$ (805)
Common stock
184
Enterprise Value
$ 15,467
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
754
1,065
1,014
Receivables
377
448
373
Inventory
680
699
777
Other
131
342
260
Current assets
1,942
2,342
2,274
Acc. Payable
241
191
193
Debt due
373
12
10
Other
319
289
336
Current liabilities
933
493
540
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(0.76)%
9.05%
16.03%
Cash flow
(455.32)%
(139.41)%
(7.57)%
Earnings
(107.46)%
(978.25)%
(407.69)%
Dividends
- -
- -
- -
Book value
4.01%
11.60%
18.47%
Insider Trading
Type
Shares
Date
Slamon Dennis
Award
4,980
05/24/22
Pyott David E I
Award
4,980
05/24/22
Meier Richard A
Award
4,980
05/24/22
Lawlis V Bryan
Award
4,980
05/24/22
Hombach Robert J.
Award
4,980
05/24/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
502
429
477
452
1,860
2021
486
502
409
450
1,846
2022
519
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.45
(0.16)
4.34
0.12
4.75
2021
0.10
0.07
(0.20)
(0.32)
(0.35)
2022
0.66
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Jean-Jacques Bienaime
Full-time employees:
3,045
City:
Novato
Address:
105 Digital Dr
IPO:
Jul 21, 2009
Website:
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Recent News